ETS1 Modulates the SENP2/HSPA8/FUNDC1 Axis to Inhibit Mitophagy in Bronchopulmonary Dysplasia

Study Background and Research Question

Bronchopulmonary dysplasia (BPD) is a chronic lung disorder predominantly affecting preterm infants, characterized by impaired alveolar development, persistent respiratory distress, and long-term pulmonary dysfunction. Despite advances in neonatal care, the incidence of BPD remains high and current therapies mostly address symptoms rather than underlying molecular drivers. Mitochondrial dysfunction and aberrant mitophagy—selective autophagic removal of damaged mitochondria—have been implicated as central pathological mechanisms that compromise lung structure and function in BPD. However, the precise regulatory pathways controlling mitophagy in this context remain incompletely defined. The recent reference study (Yang et al., 2026) addresses a fundamental question: How does the transcription factor ETS1 influence mitophagy and mitochondrial homeostasis during BPD pathogenesis, and what are the key molecular intermediates mediating this effect?

Key Innovation from the Reference Study

A central innovation of this study lies in the identification of ETS1 as a pivotal regulator that mitigates mitochondrial damage-induced mitophagy through a newly characterized SENP2/HSPA8/FUNDC1 signaling axis in the lung. Specifically, ETS1 was shown to transcriptionally upregulate SENP2, a SUMO-specific protease, which in turn removes SUMO1 modifications from the mitophagy receptor FUNDC1. This deSUMOylation event exposes the HSPA8 binding site on FUNDC1, facilitating its recognition by the chaperone and subsequent degradation. As a result, excessive mitophagy is suppressed, preserving mitochondrial integrity and ameliorating lung injury in experimental BPD.

Methods and Experimental Design Insights

The research employed a combination of cell-based and animal models to replicate key features of BPD. Hyperoxia-induced BPD was modeled both in vitro (lung epithelial cell cultures) and in vivo (neonatal mice exposed to high oxygen concentrations). ETS1 expression was manipulated via overexpression and knockdown approaches to dissect its functional role. Molecular interactions between SENP2, HSPA8, and FUNDC1 were interrogated using co-immunoprecipitation, immunoblotting, and SUMOylation assays. Functional consequences of ETS1 modulation were assessed by quantifying markers of mitochondrial damage, mitophagy activity (including LC3-II and PINK1/Parkin signaling), alveolar morphology, and overall lung injury. Additionally, SENP2 knockdown was performed to confirm its necessity in mediating ETS1’s protective effects.

Core Findings and Why They Matter

The study established several key findings:

• ETS1 overexpression significantly reduced hyperoxia-induced mitophagy and mitochondrial damage, supporting cell survival and preserving alveolar structure in both cellular and mouse BPD models (Yang et al., 2026).
• Mechanistically, ETS1 activated SENP2 transcription, increasing SENP2 protein levels and promoting the removal of SUMO1 modifications from FUNDC1.
• DeSUMOylated FUNDC1 gained affinity for the chaperone HSPA8, triggering FUNDC1 degradation and thereby limiting mitophagy.
• SENP2 knockdown reversed the protective effects of ETS1, confirming SENP2’s central role in the pathway.

This molecular cascade highlights the importance of posttranslational modification—specifically, sumoylation and deSUMOylation—in dictating the balance between mitophagy and mitochondrial preservation in the developing lung. By defining the SENP2/HSPA8/FUNDC1 axis as a downstream effector of ETS1, the study opens new avenues for targeted intervention in BPD and related disorders driven by mitochondrial quality control defects.

Comparison with Existing Internal Articles

The mechanistic insights from this BPD study resonate with findings in related research domains, including cancer and mitochondrial biology, where sumoylation-dependent regulation of protein function and turnover is increasingly recognized as a critical determinant of cellular fate. For example, the internal article “Precision SUMOylation Inhibition: 2-D08 in Translational Research” discusses the utility of 2-D08 (2’,3’,4’-trihydroxyflavone) as a selective small molecule sumoylation inhibitor for dissecting posttranslational regulatory networks. This tool compound has been benchmarked in disease modeling and mitochondrial studies, including SUMO-dependent pathways analogous to those characterized in the ETS1-SENP2 axis. Similarly, “2-D08 (2’,3’,4’-trihydroxyflavone): Selective Sumoylation Inhibitor” and “2-D08: Precision Sumoylation Inhibition” highlight 2-D08’s unique ability to block SUMO transfer to substrate proteins without affecting E1 or E2 thioester formation, allowing precise study of SUMOylation in contexts such as topoisomerase I regulation and mitochondrial function. These internal resources provide practical protocol guidance and underscore how sumoylation inhibition tools can be leveraged to interrogate disease-relevant posttranslational mechanisms, as exemplified by the SENP2/FUNDC1 pathway in BPD.

Limitations and Transferability

While the identification of the ETS1-SENP2/HSPA8/FUNDC1 axis represents a significant advance, several limitations should be noted:

• The study’s models are limited to hyperoxia-induced BPD in mice and cultured lung epithelial cells, which may only partially recapitulate the complexity of human disease.
• Direct pharmacological targeting of the SENP2/FUNDC1 interaction or ETS1 activity in vivo has yet to be validated.
• The broader impact of sumoylation modulation on other cellular processes and potential off-target effects remain to be determined.

Nevertheless, the mechanistic framework described here is likely transferable to the study of other diseases where mitophagy and SUMO-dependent signaling converge, including pulmonary fibrosis and certain cancers. The availability of selective sumoylation inhibitors, such as 2-D08, provides researchers with the means to experimentally probe these pathways in diverse cellular systems.

Protocol Parameters

• Hyperoxia exposure (BPD modeling): Neonatal mice or lung epithelial cells are typically exposed to 85-95% O₂ for 7-14 days to induce BPD-like pathology, as described in Yang et al., 2026.
• ETS1 modulation: Use of lentiviral vectors or siRNA for overexpression or knockdown; transduction efficiency and timing should be optimized based on cell type.
• SENP2 knockdown: Employ shRNA or siRNA targeting SENP2; confirm knockdown by immunoblotting prior to downstream assays.
• Mitophagy assessment: Quantification of LC3-II, PINK1/Parkin, and FUNDC1 levels by immunoblot; co-immunoprecipitation to assess FUNDC1 SUMOylation and HSPA8 binding.
• Sumoylation inhibition (workflow option): For researchers exploring the impact of sumoylation on FUNDC1 or related pathways, 2-D08 can be applied at concentrations up to 100 μM in cell-based assays, as per product documentation. Dissolve in DMSO for optimal solubility; avoid prolonged storage of solutions.

Research Support Resources

To facilitate the study of sumoylation-dependent mechanisms in BPD and related disease models, researchers may consider using 2-D08 (2’,3’,4’-trihydroxyflavone), SKU C4445, a potent and selective small molecule inhibitor of protein sumoylation. Its unique mechanism—blocking SUMO transfer without inhibiting E1 or E2 thioester formation—enables precise interrogation of posttranslational modification pathways, such as those involving SENP2 and FUNDC1. Detailed application guidelines, including solubility and storage parameters, are provided in the product information. This reagent is intended for research use only and has not been evaluated in animal models or clinical settings.